BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

362 related articles for article (PubMed ID: 33328740)

  • 1. Safety and Efficacy of Camrelizumab Combined with Apatinib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Yuan G; Cheng X; Li Q; Zang M; Huang W; Fan W; Wu T; Ruan J; Dai W; Yu W; Chen M; Guo Y; Hu X; Chen J
    Onco Targets Ther; 2020; 13():12683-12693. PubMed ID: 33328740
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
    Fan W; Yuan G; Fan H; Li F; Wu Y; Zhao Y; Yao W; Wang Y; Xue M; Yang J; Li J
    Clin Ther; 2019 Aug; 41(8):1463-1476. PubMed ID: 31303279
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatic artery infusion chemotherapy combined with camrelizumab plus rivoceranib for hepatocellular carcinoma with portal vein tumor thrombosis: a multicenter propensity score-matching analysis.
    Li Y; Guo J; Liu W; Pang H; Song Y; Wu S; Zhang F; Yan D; Chen J; An C; Li C
    Hepatol Int; 2024 May; ():. PubMed ID: 38717693
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and Safety of Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib in Patients with Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Hu Y; Zhou M; Tang J; Li S; Liu H; Hu J; Ma H; Liu J; Qin T; Yu X; Chen Y; Peng J; Zou Y; Zhang T; Xue J
    Clin Cancer Res; 2023 Oct; 29(20):4088-4097. PubMed ID: 37556120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter prospective study of TACE combined with lenvatinib and camrelizumab for hepatocellular carcinoma with portal vein tumor thrombus.
    Li X; Ding X; Liu M; Wang J; Sun W; Teng Y; Xu Y; Wu H; Li W; Zhou L; Chen J
    Cancer Med; 2023 Aug; 12(16):16805-16814. PubMed ID: 37387602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of SBRT Combined With Camrelizumab and Apatinib in HCC Patients With PVTT: Study Protocol of a Randomized Controlled Trial.
    Hu Y; Qin T; Li S; Zhang T; Xue J
    Front Oncol; 2020; 10():1589. PubMed ID: 32984021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Apatinib in Advanced Hepatocellular Carcinoma: A Multicenter Real World Retrospective Study.
    Zheng Z; Liu Z; Zhang H; Guo X; Jia X; Wang J; Meng L; Xin Y; Jiang X
    Front Pharmacol; 2022; 13():894016. PubMed ID: 35656302
    [No Abstract]   [Full Text] [Related]  

  • 8. Hepatocellular carcinoma with portal vein tumor thrombus: treatment with transarterial chemoembolization combined with sorafenib--a retrospective controlled study.
    Zhu K; Chen J; Lai L; Meng X; Zhou B; Huang W; Cai M; Shan H
    Radiology; 2014 Jul; 272(1):284-93. PubMed ID: 24708192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of transarterial chemoembolization-lenvatinib sequential therapy for the treatment of hepatocellular carcinoma with portal vein tumor thrombus: a retrospective study.
    Chen R; Li Y; Song K; Li L; Shen C; Ma P; Wang Z
    J Gastrointest Oncol; 2022 Apr; 13(2):780-786. PubMed ID: 35557575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and Safety of the PD-1 Inhibitor Lenvatinib Plus Radiotherapy in Patients with HCC with Main PVTT: Real-World Data from a Tertiary Centre.
    Li G; Zhao Y; Li K; Yang S; Xiang C; Song J; Yang Y; Li G; Dong J
    J Hepatocell Carcinoma; 2023; 10():2037-2048. PubMed ID: 37965075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Comparative Analysis of Efficacy of Apatinib Combined with Transarterial Chemoembolization and Transarterial Chemoembolization Alone in the Treatment of Hepatocellular Carcinoma with Portal Vein Tumor Thrombus.
    Sun T; Chen L; Kan X; Ren Y; Cao Y; Zhang W; Lu H; Zheng C
    J Oncol; 2022; 2022():1255133. PubMed ID: 35356254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transarterial chemoembolization combined with apatinib with or without PD-1 inhibitors in BCLC stage C hepatocellular carcinoma: A multicenter retrospective study.
    Xia WL; Zhao XH; Guo Y; Cao GS; Wu G; Fan WJ; Yao QJ; Xu SJ; Guo CY; Hu HT; Li HL
    Front Oncol; 2022; 12():961394. PubMed ID: 36249011
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Eastern Hepatobiliary Surgery Hospital/Portal Vein Tumor Thrombus Scoring System as an Aid to Decision Making on Hepatectomy for Hepatocellular Carcinoma Patients With Portal Vein Tumor Thrombus: A Multicenter Study.
    Zhang XP; Gao YZ; Chen ZH; Chen MS; Li LQ; Wen TF; Xu L; Wang K; Chai ZT; Guo WX; Shi J; Xie D; Wu MC; Yee Lau W; Cheng SQ
    Hepatology; 2019 May; 69(5):2076-2090. PubMed ID: 30586158
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of multimodality treatment for advanced hepatocellular carcinoma with portal vein tumor thrombus: patient-level network meta-analysis.
    Leung JH; Wang SY; Leung HWC; Chan ALF
    Front Oncol; 2024; 14():1344798. PubMed ID: 38434681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Transarterial Chemoembolization in Elderly Patients of Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Retrospective Study.
    Tang Q; Huang W; Liang J; Xue J
    Front Oncol; 2021; 11():646410. PubMed ID: 34307128
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a prognostic score to predict response to Yttrium-90 radioembolization for hepatocellular carcinoma with portal vein invasion.
    Spreafico C; Sposito C; Vaiani M; Cascella T; Bhoori S; Morosi C; Lanocita R; Romito R; Chiesa C; Maccauro M; Marchianò A; Mazzaferro V
    J Hepatol; 2018 Apr; 68(4):724-732. PubMed ID: 29331342
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transarterial chemoembolization (TACE) combined with sorafenib versus TACE for hepatocellular carcinoma with portal vein tumor thrombus: a systematic review and meta-analysis.
    Zhang X; Wang K; Wang M; Yang G; Ye X; Wu M; Cheng S
    Oncotarget; 2017 Apr; 8(17):29416-29427. PubMed ID: 28177886
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination.
    Ju S; Zhou C; Hu J; Wang Y; Wang C; Liu J; Yang C; Huang S; Li T; Chen Y; Bai Y; Yao W; Xiong B
    BMC Cancer; 2022 Mar; 22(1):335. PubMed ID: 35346114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of endovascular implantation of a portal vein stent combined with iodine-125 seed-strips followed by transcatheter arterial chemoembolization with sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis.
    Li S; Li L; Li B; Wang W
    Br J Radiol; 2020 Aug; 93(1112):20190279. PubMed ID: 32464068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sorafenib Versus Apatinib Both Combined Transarterial Chemoembolization for Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Comparative Retrospective Study.
    Cao Y; Sun T; Guo X; Ouyang T; Kan X; Chen L; Liang B; Wang M; Zheng C
    Front Oncol; 2021; 11():673378. PubMed ID: 34414104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.